ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | MicrobiomeTrials← Back to trialsNCT07813572
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-09Est. Completion: 2031-09
Enrollment target: 600 participants Locations- Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Other microbiome trials you might be interested in
Hepatocellular CarcinomaLiver Cancer, AdultLiver NeoplasmMetastatic Liver Cancer
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT20…
Duarte, United StatesEst. completion Dec 31, 2027
HCC - Hepatocellular Carcinoma
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving system…
Al Mansurah, EgyptEst. completion Dec 15, 2027